Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
Authors: Xavier Castellsagué
Kevin A. Ault
F. Xavier Bosch
Darron Brown
Jack Cuzick
Daron G. Ferris
Elmar A. Joura
Suzanne M. Garland
Anna R. Giuliano
Mauricio Hernandez-Avila
Warner Huh
Ole Erik Iversen
Susanne K. Kjaer
Joaquin Luna
Joseph Monsonego
Nubia Muñoz
Evan Myers
Jorma Paavonen
Punnee Pitisuttihum
Marc Steben
Cosette M. Wheeler
Gonzalo Perez
Alfred Saah
Alain Luxembourg
Heather L. Sings
Christine Velicer
Institut d'Investigació Biomedica de Bellvitge
University of Kansas Medical Center
Indiana University School of Medicine Indianapolis
Barts and The London School of Medicine and Dentistry
Augusta University
Medizinische Universitat Wien
Murdoch Children's Research Institute
Moffitt Cancer Center
Instituto Nacional de Salud Publica
University of Alabama
Helse Bergen Haukeland University Hospital
Københavns Universitet
Fundación Universitaria Sanitas
Institut du Col
National Institute of Cancer
Duke University Medical Center
Helsinki University Hospital
Mahidol University
Institut National de Sante Publique Du Quebec
University of New Mexico Health Sciences Center
Merck & Co., Inc.
Universidad del Rosario
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Dec-2016
Citation: Papillomavirus Research. Vol.2, (2016), 61-69
Abstract: © 2016 The Authors. Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.
ISSN: 24058521
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.